Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753963 | 0.87 | POLB (0.39) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL1753914 | 0.87 | POLB (0.39) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL1753519 | 0.87 | POLB (0.39) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL10034716 | 0.86 | POLB (0.41) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL16580063 | 0.86 | POLB (0.41) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL9925701 | 0.85 | GAA (0.43) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL11954968 | 0.84 | CYP4F2 (0.40) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL4258156 | 0.84 | POLB (0.48) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL13500454 | 0.83 | PRKCA (0.34) | POLBGAANPSR1PRKCACYP4F2 | |
| SCHEMBL17693803 | 0.83 | POLB (0.42) | POLBGAANPSR1PRKCACYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | DUALITY BIOLOGICS (SUZHOU) CO., LTD. (CN) | 2023-06-27 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180216107-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-08-02 | — | — | US | disclosed |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | SYNTARGA BV (NL) | 2018-05-31 | — | — | US | disclosed |
| US-9629924-B2 | Conjugates of CC-1065 analogs and bifunctional linkers | SYNTARGA BV (NL) | 2017-04-25 | — | — | US | disclosed |
| US-20170037399-A1 | CHIRAL DESIGN | WAVE LIFE SCIENCES LTD. (SG) | 2017-02-09 | — | — | US | disclosed |
| US-20160324979-A1 | METHOD FOR PURIFYING CYS-LINKED ANTIBODY-DRUG CONJUGATES | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2016-11-10 | — | — | US | disclosed |
| US-20150211006-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES USA, INC. | 2015-07-30 | — | — | US | disclosed |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2014-05-15 | — | — | US | disclosed |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | BYONDIS B.V. (NL) | 2013-08-29 | — | — | US | disclosed |
| US-8158590-B2 | Triazole-containing releasable linkers, conjugates thereof, and methods of preparation | SYNTARGA B.V. (NL) | 2012-04-17 | — | — | US | disclosed |
| US-7547718-B2 | Substituted imidazoles | PFIZER LIMITED (GB) | 2009-06-16 | — | — | US | disclosed |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | BYONDIS B.V. (NL) | 2008-12-18 | — | — | US | disclosed |
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | PFIZER LIMITED (GB) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125473-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | POLB 3099/4885GAA 425/4885NPSR1 2232/4885 |
| US-20230212182-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | POLB 1590/4885GAA 1079/4885NPSR1 2617/4885 |
| US-20140134262-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | POLB 2848/4885GAA 624/4885NPSR1 2476/4885 |
| US-20160324979-A1 | METHOD FOR PURIFYING CYS-LINKED ANTIBODY-DRUG CONJUGATES | SLC3A2, FCGR3B, CD44 | POLB 3718/4885GAA 2938/4885NPSR1 2805/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | POLB 56/4885GAA 2221/4885NPSR1 1560/4885 |
| US-20080311136-A1 | Triazole-Containing Releasable Linkers, Conjugates Thereof, and Methods of Preparation | PAICS, CD44, TRIM33 | POLB 3180/4885GAA 629/4885NPSR1 1734/4885 |
| US-20230331738-A1 | ANTI-TUMOR COMPOUND AND PREPARATION METHOD AND USE THEREOF | RCC2, REN, VHL | POLB 1590/4885GAA 1079/4885NPSR1 2617/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | POLB 2429/4885GAA 777/4885NPSR1 3100/4885 |
| US-20180153861-A1 | METHOD OF TREATING ATHEROSCLEROSIS IN HIGH TRIGLYCERIDE SUBJECTS | CETP, MTTP, APOB | POLB 3082/4885GAA 716/4885NPSR1 2348/4885 |
| US-11685742-B2 | Anti-tumor compound and preparation method and use thereof | RCC2, REN, VHL | POLB 1590/4885GAA 1079/4885NPSR1 2617/4885 |
| US-20150211006-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | POLB 56/4885GAA 2221/4885NPSR1 1560/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | POLB 56/4885GAA 2221/4885NPSR1 1560/4885 |
| US-20180147289-A9 | Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
| US-20180216108-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RNGTT, NSUN2, POLRMT | POLB 42/4885GAA 656/4885NPSR1 3245/4885 |
| US-20130224227-A1 | NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS | PCNA, DCLRE1A, CDC5L | POLB 230/4885GAA 971/4885NPSR1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.